Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Not applicable

3D Printed vs CAD/CAM Rehabilitation of Primary Anterior Teeth Loss

NCT07752147 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2025-07-11
Last updated
2026-09-25

Condition(s) studied

Modified Fixed Bridge

Investigational drug(s) / intervention(s)

3D Printed modified fixed bridgeCAD/CAM fabricated modified fixed bridge

3D Printed modified fixed bridge: the 3D Printed modified fixed appliances compared to CAD/CAM fabricated ones for rehabilitation of premature loss of anterior teeth

CAD/CAM fabricated modified fixed bridge: the CAD/CAM fabricated modified fixed bridge used a active control

Study summary

compare 3D Printed versus CAD/CAM fabricated modified fixed appliance for rehabilitation of premature loss of anterior teeth in preschool children

Eligibility

Sex
ALL
Min age
3 Years
Max age
5 Years
Healthy volunteers
No
Inclusion Criteria: 1. Healthy children (ASA I or II) 2. Premature loss of one to four maxillary primary incisors 3. At least 6 months remaining before the expected eruption of the permanent successor 4. Presence of sufficient healthy abutment teeth (primary canines) 5. Adequate oral hygiene (Plaque Index ≤1). 6. Cooperative child (Frankl Behavior Rating 3, 4). Exclusion Criteria: 1. Children with craniofacial anomalies or syndromes (e.g., cleft lip and palate). 2. Children with developmental dental anomalies affecting the anterior region (e.g., hypodontia, severe enamel defects). 3. Severe gingivitis or periodontal disease around the abutment teeth. 4. Deep bite, severe malocclusion, or traumatic occlusion that could interfere with appliance function. 5. Parafunctional habits that could increase appliance failure( Bruxism, Nail biting, Biting hard objects). 6. Persistent oral habits that may affect appliance stability

Primary outcome measure(s)

  • Clinical survival rate — 12 months
    Debonding, breakage of appliance ( failure causes)
  • Gingival health — 12 months
    Gingival index will be assessed by clinician
  • Esthetic evaluation — 12 months
    child and parent evaluation of restoring child esthetics using visual analog scale

Trial sites (1)

FacilityCityRegionStatus
Faculty of Dentistry Tanta Egypt
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07752147 on ClinicalTrials.gov ↗ ← All trials in Egypt